Lexagene Holdings - CEO, Dr. Jack Regan.
CEO, Dr. Jack Regan.
Source: LexaGene Holdings Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • LexaGene (LXG) webinar by UC Davis professor on use of MiQLab system for Diagnosis of urinary tract infections
  • This webinar will provide background information on the difficulties of accurately diagnosing urinary tract infections with conventional technologies
  • Also, the course will provide background information on the rising threat of antimicrobial resistance
  • Dr. Sykes is a Professor of Small Animal Internal Medicine (Infectious Diseases)
  • Her research focus is infectious diseases of dogs and cats, especially those of public health significance
  • LexaGene Holdings (LXG)  is down 6.45 per cent, trading at C$0.14 at 11:21 am EST


LexaGene Holdings (LXG) and Dr. Jane Sykes will present a webinar entitled, “The Wave of the Future: In-Clinic PCR Diagnosis.”

LexaGene has initially focused on commercializing the MiQLab System for automated, multiplexing PCR-based syndromic testing in veterinary clinics.

This will be a live event hosted by DVM360 and moderated by Adam Christman, DVM, MBA. The event will commence on Tuesday, July 26, at 7 pm EST. 

The webinar will provide background information on the difficulties of accurately diagnosing urinary tract infections with conventional technologies.

Also, the course will provide background information on the rising threat of antimicrobial resistance.

The webinar will be followed by an overview of PCR and how veterinarians can use genomic testing to make rapid evidence-based decisions in the clinic by utilizing the MiQLab System to rapidly screen samples for 10 common pathogens and 33 markers for antimicrobial resistance factors.

Dr. Sykes is a Professor of Small Animal Internal Medicine (Infectious Diseases) and the Executive Director of Innovation and Entrepreneurship in the School of Veterinary Medicine (SVM) at UC Davis.

Her research focus is infectious diseases of dogs and cats, especially those of public health significance.

Dr. Sykes obtained her veterinary degree and Ph.D. at the University of Melbourne and her MBA from the University of Georgia.

She also completed her residency at the University of Minnesota. She has also won awards, having been granted the recipient of numerous awards and the author of many scientific publications.

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics.

LexaGene Holdings (LXG)  is down 6.45 per cent, trading at C$0.14 at 11:21 am EST.

More From The Market Herald

" Nextech AR (CSE:NTAR) (OTCQB:NEXCF) announces new 3D modeling contracts

Nextech AR Solutions (NTAR) has signed numerous new 3D modeling deals throughout the month of July and early August, 2022.

" Quarterhill (TSX:QTRH) revenue soars in Q2 2022

Quarterhill (QTRH) has announced financial results for its second quarter ended June 30, 2022.

" Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023

Aleafia Health (AH) reported its financial results for the three months ended June 30, 2022.

" UniDoc (CSE:UDOC) signs agreement to provide telehealth services in Kenya

UniDoc Health (UDOC) has signed a master equipment deployment and services agreement with Claron Health to provide telehealth services in Kenya.